Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2017, Cilt: 3 Sayı: 3, 157 - 163, 28.09.2017

Öz

Kaynakça

  • 1. Spencer FA, Lessard D, Emery C, Reed et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167:1471-1475.
  • 2. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164:1653.
  • 3. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58.
  • 4. K. Brækkan, * E. B. Mathıesen, _ I. Njølstad, _ T. Wılsgaard, et al. Mean Platelet Volume İs A Risk Factor For Venous Thromboembolism: The Tromsø Studys. Journal Of Thrombosis And Haemostasis, 8: 157–162
  • 5. Ferroni P, Guadagni F, Riondino S, et al. Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica. 2014;99(10):1638-1644.
  • 6. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010;14(1):28-32.
  • 7. Amin MA, Amin AP, Kulkarni HR. Platelet distribution width (PDW) is increased in -vaso-occlusive crisis in sickle cell dis- ease. Ann Hematol 2004; 83 (6): 331-335
  • 8. Kaito, K., Otsubo, H., Usui, N., Yoshida, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. British journal of haematology 2005;128(5), 698-702.
  • 9. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis As A Prognostic Factor For Survival İn Patients With Metastatic Renal Cell Carcinoma. Cancer. 2006 Oct 15;107 (8):1793-800
  • 10. Cil H, Yavuz C, Islamoglu Y, et al. Platelet count and mean platelet volume in patients with in-hospital deep venous thrombosis. Clin Appl Thromb Hemost 2012;18:650-3.
  • 11. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-5505.
  • 12. Khorana AA, Kuderer NM, Culakova E, Lyman GH, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
  • 13. Sev Sevuk U, Altindag R, Bahadir MV, Ay N, et al. Value of Platelet Indices in Identifying Complete Resolution of Thrombus in Deep Venous Thrombosis Patients. Indian Journal of Hematology & Blood Transfusion. 2015;31(1):71-76.
  • 14. Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, et al. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an In- dian scena. J Clin Pathol 2006; 59 (2): 146-149.
  • 15. Mutlu H, Artis Ta, Erden A, Akca Z. Alteration İn Mean Platelet Volume And Platicrit Values İn Patients With Cancer That Developed Thrombosis. Clin Appl Thromb Hemost 2012;19:331-3.
  • 16. Scappaticci Fa, Skillings Jr, Holden Sn, et al. Arterial Thromboembolic Events İn Patients With Metastatic Carcinoma Treated With Chemotherapy And Bevacizumab. J Natl Cancer Inst. 2007; 99 (16):1232-1239.
  • 17. H. Mutlu, V. Berk, H. Karaca, A. Erden, et al. Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume İn Patients With Metastatic Colon Cancer Clın Appl Thromb Hemost 2012 18: 546

Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers

Yıl 2017, Cilt: 3 Sayı: 3, 157 - 163, 28.09.2017

Öz

Kemoterapi alan kanser hastalarında tromboz eğiliminin
arttığı günümüzde oldukça iyi bilinmektedir. Biz bu çalışmamızda bu hastalarda MPV
ve PDW'daki değişiklikleri araştırdık. 169 gastrik ve 176 kolorektal kanser
tanılı, 6 farklı kemoterapi protokolü uygulanan toplam 345 hasta çalışmamıza
alındı. Medyan yaş 59 (23-80) olup 155’i  erkekti. Kemoterapi öncesi, ortası ve
sonrasında trombosit sayısı, MPV ve PDW değerleri ölçüldü. Kemoterapi alan
hastalarda trombosit sayısı ve MPV değerleri belirgin olarak azalırken PDW değerlerinin
arttığı saptandı. Ayrıca, MPV, PDW değerleri ve vasküler tromboz, genel veya
progresyonsuz sağkalım değişiklikleri arasında istatistiksel olarak anlamlı bir
ilişki olmadığı görüldü.

Kaynakça

  • 1. Spencer FA, Lessard D, Emery C, Reed et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167:1471-1475.
  • 2. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164:1653.
  • 3. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58.
  • 4. K. Brækkan, * E. B. Mathıesen, _ I. Njølstad, _ T. Wılsgaard, et al. Mean Platelet Volume İs A Risk Factor For Venous Thromboembolism: The Tromsø Studys. Journal Of Thrombosis And Haemostasis, 8: 157–162
  • 5. Ferroni P, Guadagni F, Riondino S, et al. Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica. 2014;99(10):1638-1644.
  • 6. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010;14(1):28-32.
  • 7. Amin MA, Amin AP, Kulkarni HR. Platelet distribution width (PDW) is increased in -vaso-occlusive crisis in sickle cell dis- ease. Ann Hematol 2004; 83 (6): 331-335
  • 8. Kaito, K., Otsubo, H., Usui, N., Yoshida, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. British journal of haematology 2005;128(5), 698-702.
  • 9. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis As A Prognostic Factor For Survival İn Patients With Metastatic Renal Cell Carcinoma. Cancer. 2006 Oct 15;107 (8):1793-800
  • 10. Cil H, Yavuz C, Islamoglu Y, et al. Platelet count and mean platelet volume in patients with in-hospital deep venous thrombosis. Clin Appl Thromb Hemost 2012;18:650-3.
  • 11. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-5505.
  • 12. Khorana AA, Kuderer NM, Culakova E, Lyman GH, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
  • 13. Sev Sevuk U, Altindag R, Bahadir MV, Ay N, et al. Value of Platelet Indices in Identifying Complete Resolution of Thrombus in Deep Venous Thrombosis Patients. Indian Journal of Hematology & Blood Transfusion. 2015;31(1):71-76.
  • 14. Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, et al. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an In- dian scena. J Clin Pathol 2006; 59 (2): 146-149.
  • 15. Mutlu H, Artis Ta, Erden A, Akca Z. Alteration İn Mean Platelet Volume And Platicrit Values İn Patients With Cancer That Developed Thrombosis. Clin Appl Thromb Hemost 2012;19:331-3.
  • 16. Scappaticci Fa, Skillings Jr, Holden Sn, et al. Arterial Thromboembolic Events İn Patients With Metastatic Carcinoma Treated With Chemotherapy And Bevacizumab. J Natl Cancer Inst. 2007; 99 (16):1232-1239.
  • 17. H. Mutlu, V. Berk, H. Karaca, A. Erden, et al. Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume İn Patients With Metastatic Colon Cancer Clın Appl Thromb Hemost 2012 18: 546
Toplam 17 adet kaynakça vardır.

Ayrıntılar

Bölüm Makaleler
Yazarlar

Bilal Toka

Müzeyyen Arslaner Bu kişi benim

Cemil Bilir Bu kişi benim

Hüseyin Engin Bu kişi benim

Şehmuz Ertop Bu kişi benim

Yayımlanma Tarihi 28 Eylül 2017
Gönderilme Tarihi 28 Eylül 2017
Kabul Tarihi 26 Eylül 2017
Yayımlandığı Sayı Yıl 2017 Cilt: 3 Sayı: 3

Kaynak Göster

APA Toka, B., Arslaner, M., Bilir, C., Engin, H., vd. (2017). Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers. Journal of Human Rhythm, 3(3), 157-163.
AMA Toka B, Arslaner M, Bilir C, Engin H, Ertop Ş. Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers. Journal of Human Rhythm. Eylül 2017;3(3):157-163.
Chicago Toka, Bilal, Müzeyyen Arslaner, Cemil Bilir, Hüseyin Engin, ve Şehmuz Ertop. “Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers”. Journal of Human Rhythm 3, sy. 3 (Eylül 2017): 157-63.
EndNote Toka B, Arslaner M, Bilir C, Engin H, Ertop Ş (01 Eylül 2017) Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers. Journal of Human Rhythm 3 3 157–163.
IEEE B. Toka, M. Arslaner, C. Bilir, H. Engin, ve Ş. Ertop, “Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers”, Journal of Human Rhythm, c. 3, sy. 3, ss. 157–163, 2017.
ISNAD Toka, Bilal vd. “Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers”. Journal of Human Rhythm 3/3 (Eylül 2017), 157-163.
JAMA Toka B, Arslaner M, Bilir C, Engin H, Ertop Ş. Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers. Journal of Human Rhythm. 2017;3:157–163.
MLA Toka, Bilal vd. “Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers”. Journal of Human Rhythm, c. 3, sy. 3, 2017, ss. 157-63.
Vancouver Toka B, Arslaner M, Bilir C, Engin H, Ertop Ş. Changes in MPVand PDW Values in Patients Receiving Chemotherapy for Colon and Gastric Cancers. Journal of Human Rhythm. 2017;3(3):157-63.